Cerebrolysin (215mg)

What is Cerebrolysin?

A standardized peptide preparation derived from porcine brain tissue. Approved in 50+ countries for stroke, dementia, and neurotrauma research.

Listed vial contents: 215mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Cerebrolysin is a peptide preparation produced by standardized enzymatic breakdown of purified porcine brain proteins. The resulting low-molecular-weight (<10 kDa) peptides and free amino acids mimic the activity of endogenous neurotrophic factors (BDNF, NGF, GDNF, CNTF), modulate neuroinflammation, and support neuronal survival, neurogenesis, and synaptic plasticity.

What are the research questions?

• Acute ischemic stroke: CARS, CASTA, and ESCAS trials reported improved functional recovery and reduced disability when initiated within 24-72 hours.
• Traumatic brain injury (TBI): CAPTAIN II trial showed enhanced recovery on the Glasgow Outcome Scale Extended at 90 days post-injury.
• Vascular and Alzheimer-type dementia: Meta-analyses report modest cognitive improvements on ADAS-cog and MMSE.
• Pediatric neurodevelopment: Used in research models of developmental delay and perinatal hypoxic injury.

What does the published work describe?

Bornstein NM et al. (CARS, 2018) — improved early motor recovery after ischemic stroke. Muresanu DF et al. (CAPTAIN II, 2020) — significantly improved 90-day outcomes in moderate-severe TBI. Cochrane reviews characterize the evidence as moderate-quality.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Bornstein NM et al. CARS trial 2018
2. Muresanu DF et al. CAPTAIN II 2020

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.

How is Cerebrolysin handled in the lab?

Plan a Cerebrolysin stock solution from the sequence, the listed molecular weight (<10000 g/mol (peptide mixture)) and, when reported for the same lot, net peptide content. Test-dissolve a small portion first, store the powder sealed, cold and dry, and split solutions into single-use aliquots. These are laboratory handling notes, not administration guidance.

• Peptide solubility: choosing a lab solvent
• Stock solution molarity and concentration math
• Lyophilized storage, aliquoting and freeze-thaw
• Fmoc vs Boc synthesis and the impurities they leave